Impact of opioid analgesics on the efficacy of immune checkpoint inhibitors in a lung cancer population
Abstract Objective A retrospective clinical study was conducted to compare the prognosis between the opioid analgesic (OA) treated and OA-untreated groups and to evaluate the effect of opioid analgesics on the efficacy of immune checkpoint inhibitors (ICIs) in the treatment of advanced lung cancer p...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2022-11-01
|
| Series: | BMC Pulmonary Medicine |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12890-022-02210-9 |
| _version_ | 1828178728767717376 |
|---|---|
| author | Xiaoyuan Yu Li Zhao Bin Song |
| author_facet | Xiaoyuan Yu Li Zhao Bin Song |
| author_sort | Xiaoyuan Yu |
| collection | DOAJ |
| description | Abstract Objective A retrospective clinical study was conducted to compare the prognosis between the opioid analgesic (OA) treated and OA-untreated groups and to evaluate the effect of opioid analgesics on the efficacy of immune checkpoint inhibitors (ICIs) in the treatment of advanced lung cancer patients. In addition, a subgroup analysis of the clinical characteristics of the enrolled patients was performed to explore possible influencing factors. Methods This study reviewed the medical records of eligible patients who received ICIs at our institution. The clinicopathological features and clinical outcomes were compared. Also, the use of OA was collected. Patient survival, the incidence of immune-related adverse events (irAEs), and other baseline variables were examined in both cohorts according to whether OA was used. Results A total of 132 patients were included in the study. Of them, 39 (29.5%) were in the OA-treated group. No significant differences in baseline characteristics were observed between the OA-treated and untreated groups. The combined application of OA treatment significantly shortened progression-free survival (PFS) (P < 0.001) and overall survival (OS) (P = 0.002). However, both groups experienced similar incidences and gradations of irAEs. According to multivariate analysis, OA treatment resulted in significantly worse PFS (HR = 4.994, 95% CI 3.217–7.753, P < 0.001) and OS (HR = 3.618, 95% CI 2.030–6.240, P < 0.001). Conclusions Clinical outcomes of ICIs were significantly diminished in a cohort of Chinese patients with advanced lung cancer receiving OA therapy. |
| first_indexed | 2024-04-12T05:21:35Z |
| format | Article |
| id | doaj.art-ad664810d3464d53add59c7d7140de18 |
| institution | Directory Open Access Journal |
| issn | 1471-2466 |
| language | English |
| last_indexed | 2024-04-12T05:21:35Z |
| publishDate | 2022-11-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Pulmonary Medicine |
| spelling | doaj.art-ad664810d3464d53add59c7d7140de182022-12-22T03:46:28ZengBMCBMC Pulmonary Medicine1471-24662022-11-0122111010.1186/s12890-022-02210-9Impact of opioid analgesics on the efficacy of immune checkpoint inhibitors in a lung cancer populationXiaoyuan Yu0Li Zhao1Bin Song2First Hospital of Shanxi Medical UniversityThird Hospital of Shanxi Medical University, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Tongji Shanxi HospitalThird Hospital of Shanxi Medical University, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Tongji Shanxi HospitalAbstract Objective A retrospective clinical study was conducted to compare the prognosis between the opioid analgesic (OA) treated and OA-untreated groups and to evaluate the effect of opioid analgesics on the efficacy of immune checkpoint inhibitors (ICIs) in the treatment of advanced lung cancer patients. In addition, a subgroup analysis of the clinical characteristics of the enrolled patients was performed to explore possible influencing factors. Methods This study reviewed the medical records of eligible patients who received ICIs at our institution. The clinicopathological features and clinical outcomes were compared. Also, the use of OA was collected. Patient survival, the incidence of immune-related adverse events (irAEs), and other baseline variables were examined in both cohorts according to whether OA was used. Results A total of 132 patients were included in the study. Of them, 39 (29.5%) were in the OA-treated group. No significant differences in baseline characteristics were observed between the OA-treated and untreated groups. The combined application of OA treatment significantly shortened progression-free survival (PFS) (P < 0.001) and overall survival (OS) (P = 0.002). However, both groups experienced similar incidences and gradations of irAEs. According to multivariate analysis, OA treatment resulted in significantly worse PFS (HR = 4.994, 95% CI 3.217–7.753, P < 0.001) and OS (HR = 3.618, 95% CI 2.030–6.240, P < 0.001). Conclusions Clinical outcomes of ICIs were significantly diminished in a cohort of Chinese patients with advanced lung cancer receiving OA therapy.https://doi.org/10.1186/s12890-022-02210-9Lung cancerImmune checkpoint inhibitorsDrug resistanceOpioid analgesicsGut microbiota |
| spellingShingle | Xiaoyuan Yu Li Zhao Bin Song Impact of opioid analgesics on the efficacy of immune checkpoint inhibitors in a lung cancer population BMC Pulmonary Medicine Lung cancer Immune checkpoint inhibitors Drug resistance Opioid analgesics Gut microbiota |
| title | Impact of opioid analgesics on the efficacy of immune checkpoint inhibitors in a lung cancer population |
| title_full | Impact of opioid analgesics on the efficacy of immune checkpoint inhibitors in a lung cancer population |
| title_fullStr | Impact of opioid analgesics on the efficacy of immune checkpoint inhibitors in a lung cancer population |
| title_full_unstemmed | Impact of opioid analgesics on the efficacy of immune checkpoint inhibitors in a lung cancer population |
| title_short | Impact of opioid analgesics on the efficacy of immune checkpoint inhibitors in a lung cancer population |
| title_sort | impact of opioid analgesics on the efficacy of immune checkpoint inhibitors in a lung cancer population |
| topic | Lung cancer Immune checkpoint inhibitors Drug resistance Opioid analgesics Gut microbiota |
| url | https://doi.org/10.1186/s12890-022-02210-9 |
| work_keys_str_mv | AT xiaoyuanyu impactofopioidanalgesicsontheefficacyofimmunecheckpointinhibitorsinalungcancerpopulation AT lizhao impactofopioidanalgesicsontheefficacyofimmunecheckpointinhibitorsinalungcancerpopulation AT binsong impactofopioidanalgesicsontheefficacyofimmunecheckpointinhibitorsinalungcancerpopulation |